Macada Holding, Inc. Announces Its Subsidiary Lyfetec, Inc. Has Signed a Purchase Agreement for Three Medical Formulas With a Ge

  Macada Holding

,

 Inc. (PINKSHEETS: MCDA) announced that its subsidiary Lyfetec, Inc. has signed a purchase agreement for three medical treatment formulas and the rights to patent all three formulas in the United States under the Lyfetec name.

Dr. Karsten Klingellioller, a bio-chemist, created these three skin disease treatment products. Dr. Kingellioller, who presently holds four doctors degrees, has completed U.S. and European clinical trials and patents on a variety of cancer and skin products throughout his career.

The formulas acquired by Lyfetec, Inc. have anti-aging and skin cell rejuvenation additives that have been added for Lyfetec's new Bio-Skin product line. Before Lyfetec's request to add anti-aging and skin cell rejuvenation additives, Dr. Karsten's formulas meet FDA and CE safety standards to treat melanoma - neurodermatitis / atopic dermatitis - psoriasis - cradle cap and other conditions. Lyfetec, Inc. will be re-testing with the new additives for the Lyfetec Bio-Skin line which will be marketed as a treatment lotion-shampoo and soap while entering Stage I of FDA new clinical trials to support and verify its CE and FDA documentation with the prior products which treats many types of skin diseases and some skin cancers.

Lyfetec plans to complete the exact FDA study which had trails in the U.S. and Europe.

Mr. Mellone, the company's President, said: "An important new focus here, is to establish a new marketing approach, direct to consumer, hospitals and doctors, such that families and individuals can become more connected to their health and obtain the identify of major illness at the earliest possible stage. These products we have been in negotiations with for month, visit www.boi-skin.us. We are also closing other products in the weeks to come that we have been working on since last year."

Safe Harbor Provision

This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Macada Holding, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, the availability of technical personnel, changes in technology and competition.

Contact: Ron Ritter 954-782-2056